Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunity to measles and varicella after childhood cancer therapy
2024-511182-10-01Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Sep 2024
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of measles, mumps, and rubella vaccine and varicella virus vaccine live in measles and chickenpox (2 arms), sponsored by Region Västra Götaland. Primary endpoints: Difference in VZ IgG antibody levels before and after revaccination against chickenpox and Difference in measles IgG antibody level before and after revaccination against measles. Planned start Sep 2024; status: authorised.
02
Drugs
measles, mumps, and rubella vaccinevaricella virus vaccine live
03
Conditions
measleschickenpox
Beyond the preview
Go deeper on 2024-511182-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511182-10-01.